HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Compass Therapeutics to ($0.40) from ($0.57), while the street consensus is ($0.36) for the year.
• Compass reported a Q4 EPS of ($0.09), beating consensus by $0.01, and faces a near‑term binary catalyst as the Phase 2/3 COMPANION‑002 tovecimig trial will report prespecified PFS and OS analyses in April.
• Analyst sentiment is broadly positive with a consensus rating of “Moderate Buy” and an average price target of $13.00, and institutional investors hold roughly 68% of the stock.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for Compass Therapeutics in a report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.40) per share for the year, up from their prior forecast of ($0.57). The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' FY2028 earnings at ($0.52) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Several other equities analysts also recently commented on CMPX. Leerink Partners upgraded Compass Therapeutics to a "strong-buy" rating in a research report on Wednesday, November 26th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a "buy" rating and a $15.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. Citigroup began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued an "outperform" rating on the stock. Finally, Canaccord Genuity Group set a $13.00 price target on Compass Therapeutics in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $5.51 on Monday. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.88. The company has a market capitalization of $992.30 million, a P/E ratio of -12.81 and a beta of 1.48. The company has a fifty day moving average of $5.90 and a 200 day moving average of $4.82.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CMPX. Suvretta Capital Management LLC lifted its stake in shares of Compass Therapeutics by 0.6% during the 4th quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company's stock worth $76,159,000 after acquiring an additional 81,220 shares during the last quarter. Vivo Capital LLC grew its position in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after acquiring an additional 3,502,000 shares during the last quarter. BVF Inc. IL increased its stake in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after purchasing an additional 3,014,842 shares during the period. Vanguard Group Inc. increased its stake in Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company's stock worth $24,720,000 after purchasing an additional 2,212,794 shares during the period. Finally, State Street Corp lifted its position in shares of Compass Therapeutics by 57.4% during the fourth quarter. State Street Corp now owns 4,890,525 shares of the company's stock worth $26,262,000 after purchasing an additional 1,784,012 shares during the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Key Compass Therapeutics News

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Phase 2/3 COMPANION‑002 tovecimig trial hit the prespecified event threshold (≈80% OS events), so prespecified PFS and OS analyses are expected to be reported in April — a near-term binary clinical readout that could materially move the stock. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Management opened expansion cohorts for CTX‑8371 in TNBC and NSCLC and will add a Hodgkin lymphoma cohort after an additional response — further clinical activity and potential signals that can drive upside. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Q4 results: CMPX reported ($0.09) EPS, beating the consensus ($0.10) loss by $0.01 — a small beat that can be supportive for sentiment. View Press Release
• Neutral Sentiment: HC Wainwright published 2026 quarterly EPS forecasts (Q1: ‑$0.09, Q2: ‑$0.10, Q3: ‑$0.10, Q4: ‑$0.11) and a full‑year loss estimate of ‑$0.36 — these reinforce expectations for continued operating losses but are broadly in line with prior guidance. MarketBeat CMPX
• Negative Sentiment: Reports indicate a “large increase” in short interest in early March, but the published figures show 0 shares and NaN changes (data appears inconsistent). If short interest is actually rising, that would be a bearish signal; the current reporting ambiguity may add volatility. MarketBeat CMPX

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.